Skip to content
Black Friday — 30% OFFFree shipping on orders of £99 or more
  1. Home
  2. Hormonal Health & Growth
  3. Raloxifene (20mg/capsule), 60 Capsules
Hormonal Health

Raloxifene (20mg/capsule), 60 Capsules

Raloxifene is a selective estrogen receptor modulator (SERM) that exhibits tissue-specific agonist and antagonist activity at estrogen receptors (ERs).

Presentation: Raloxifene (20mg/capsule), 60 Capsules.

Illustrative packaging generated with AI.

Original price was: £99.95.Current price is: £69.97.

Available on request in the United Kingdom

Ask an advisor
An advisor contacts you and the partner pharmacy checks whether and how it can proceed. A valid prescription, or an assessment through an authorised telemedicine service, may be required.
  • Partner pharmacy
  • Personal assistance
  • Discreet delivery
  • Presentation
    Raloxifene (20mg/capsule), 60 Capsules

Shipping & Delivery

  • Normally dispatched within 24 hours of payment confirmation.
  • USPS Regular Shipping · £11.95 · Approx. 3–5 business days
  • FedEx 2 Days Delivery · £28.99 · Approx. 2 business days
  • FedEx Overnight Delivery · £40.99 · Approx. 1 business day

For laboratory research only.

Not for human or veterinary use.

Composition and product details

Overview

Raloxifene is a selective estrogen receptor modulator (SERM) that exhibits tissue-specific agonist and antagonist activity at estrogen receptors (ERs). It interacts with ERα and ERβ, influencing gene transcription and receptor-mediated signaling pathways.

This compound undergoes hepatic metabolism primarily via glucuronidation, producing inactive glucuronide conjugates.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only

Properties

Chemical Formula C28H27NO4S
Synonyms Keoxifene, LY156758
Molar Mass 473.58 g/mol
CAS Number 84449-90-1
PubChem CID 5035
Total Compound Content 5 grams
Shelf Life 36 months

Research

Raloxifene binds competitively to both estrogen receptor subtypes (ERα and ERβ), producing conformational changes in the receptor that recruit different coactivator/corepressor complexes depending on the target tissue — the structural basis of its tissue-selective agonist/antagonist profile. In bone tissue, this conformation favors estrogen-agonist-like signaling, supporting research into its effects on bone mineral density and osteoclast activity. In breast and uterine tissue, the resulting conformation instead favors antagonist activity, a key research contrast point against tamoxifen, which retains partial agonist activity in the endometrium. Research models frequently compare raloxifene against tamoxifen and other SERMs to characterize how ligand structure determines coactivator recruitment and downstream tissue selectivity. Unlike tamoxifen, raloxifene does not require CYP2D6-mediated metabolism to an active form, making it a useful comparative tool in studies of SERM pharmacokinetics and metabolic activation pathways. Independently third-party HPLC-tested; COA available per batch.

Lab Results

Results refer to the tested sample. Check the batch and date in the report.

SC Raloxifene (HPLC)
August 4, 2026

FAQ

What makes raloxifene’s tissue selectivity distinct from tamoxifen’s in receptor pharmacology research?

Both compounds bind the estrogen receptor, but the resulting receptor conformation differs in ways that alter coactivator/corepressor recruitment by tissue. Raloxifene’s conformation favors antagonist activity in both breast and endometrial tissue, whereas tamoxifen retains partial agonist activity in the endometrium.

This divergence makes head-to-head SERM studies a common approach for mapping how structural differences in ligands translate into tissue-specific transcriptional outcomes.

How is raloxifene used in bone metabolism research models?

Because raloxifene’s receptor conformation in bone tissue favors estrogen-agonist-like signaling, it is used in osteoblast/osteoclast culture models and in vivo bone density studies to examine estrogen-receptor-mediated effects on bone turnover, independent of the antagonist activity it shows in reproductive tissue.

What distinguishes raloxifene’s metabolic pathway from other SERMs in pharmacokinetic research?

Raloxifene undergoes extensive glucuronidation rather than requiring CYP2D6-mediated bioactivation, unlike tamoxifen, which depends on CYP2D6 conversion to its active metabolite endoxifen. This makes raloxifene a useful comparator in research examining how metabolic activation requirements affect SERM activity and inter-individual variability tied to CYP2D6 polymorphisms.

Capsule excipients are not specified in the available product documentation.

Original price was: £99.95.Current price is: £69.97.